Equities research analysts predict that Audentes Therapeutics Inc (NASDAQ:BOLD) will report earnings of ($1.08) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Audentes Therapeutics’ earnings, with estimates ranging from ($1.23) to ($0.98). Audentes Therapeutics reported earnings of ($0.97) per share during the same quarter last year, which would indicate a negative year over year growth rate of 11.3%. The firm is scheduled to issue its next quarterly earnings results on Tuesday, November 5th.
According to Zacks, analysts expect that Audentes Therapeutics will report full year earnings of ($4.25) per share for the current fiscal year, with EPS estimates ranging from ($4.67) to ($3.64). For the next financial year, analysts forecast that the company will report earnings of ($4.38) per share, with EPS estimates ranging from ($5.03) to ($3.39). Zacks’ earnings per share calculations are an average based on a survey of research analysts that cover Audentes Therapeutics.
Audentes Therapeutics (NASDAQ:BOLD) last issued its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported ($1.01) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.08) by $0.07. During the same period in the previous year, the firm earned ($0.85) earnings per share.
Several equities research analysts recently weighed in on BOLD shares. Zacks Investment Research cut Audentes Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, August 1st. ValuEngine raised Audentes Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Saturday, July 27th. Mizuho reaffirmed a “buy” rating and issued a $45.00 price target on shares of Audentes Therapeutics in a research note on Wednesday, August 7th. HC Wainwright set a $48.00 price target on Audentes Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, May 8th. Finally, Leerink Swann reaffirmed an “outperform” rating and issued a $48.00 price target (up from $37.00) on shares of Audentes Therapeutics in a research note on Wednesday, April 17th. Two investment analysts have rated the stock with a sell rating, three have given a hold rating, eleven have issued a buy rating and two have given a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $39.99.
In other news, Director Louis G. Lange sold 21,000 shares of the stock in a transaction on Monday, June 24th. The stock was sold at an average price of $37.79, for a total value of $793,590.00. Following the sale, the director now directly owns 290,001 shares of the company’s stock, valued at $10,959,137.79. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Corporate insiders own 5.30% of the company’s stock.
Several large investors have recently made changes to their positions in the company. Bank of New York Mellon Corp increased its holdings in shares of Audentes Therapeutics by 19.1% in the fourth quarter. Bank of New York Mellon Corp now owns 152,232 shares of the biotechnology company’s stock valued at $3,245,000 after purchasing an additional 24,462 shares during the last quarter. Northern Trust Corp grew its stake in shares of Audentes Therapeutics by 13.6% in the fourth quarter. Northern Trust Corp now owns 436,596 shares of the biotechnology company’s stock valued at $9,308,000 after acquiring an additional 52,183 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in shares of Audentes Therapeutics by 232.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 564,047 shares of the biotechnology company’s stock valued at $12,025,000 after acquiring an additional 394,602 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Audentes Therapeutics by 16.8% in the fourth quarter. Geode Capital Management LLC now owns 394,455 shares of the biotechnology company’s stock valued at $8,409,000 after acquiring an additional 56,856 shares in the last quarter. Finally, Metropolitan Life Insurance Co. NY grew its stake in shares of Audentes Therapeutics by 441.7% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 12,556 shares of the biotechnology company’s stock valued at $268,000 after acquiring an additional 10,238 shares in the last quarter. 96.72% of the stock is currently owned by hedge funds and other institutional investors.
BOLD stock traded up $0.05 during midday trading on Friday, hitting $34.13. The stock had a trading volume of 6,094 shares, compared to its average volume of 515,000. The stock has a market cap of $1.55 billion, a price-to-earnings ratio of -10.06 and a beta of 1.70. The stock’s 50-day moving average price is $37.21. Audentes Therapeutics has a 52-week low of $17.95 and a 52-week high of $41.65.
About Audentes Therapeutics
Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.
Featured Article: What is a resistance level?
Get a free copy of the Zacks research report on Audentes Therapeutics (BOLD)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.